Dr. Raphael on the Clinical Implications of the CLL14 Trial

Video

In Partnership With:

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the utility of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

The CLL14 trial was one of the first trials to show that the combination of novel agents can provide a greater or more complete response than that achieved with standard regimens, says Raphael. In the trial, the BCL-2 inhibitor, venetoclax (Venclexta), was combined with obinutuzumab (Gazyva) and compared with the standard treatment comprised of chlorambucil and obinutuzumab.

After a median follow-up of 28.1 months, progression-free survival rate at 24 months was significantly higher in the venetoclax/obinutuzumab arm, at 88.2%, than in the chlorambucil/obinutuzumab arm, at 64.1%. The results of this trial are two-fold, says Raphael. In the 1 year of treatment, patients experienced higher rates of response with the venetoclax/obinutuzumab combination as well as higher levels of minimal residual disease negativity; this translated into better responses, particularly for high-risk patients, concludes Raphael.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,